CDXDA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Cardiex Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
5
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Cardiex Limited
π Performance
Price History
+342.86%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.47
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in CDXDA
0
π Total Capital Earnings
N/A
π Average investment frequency
101 weeks
π΅ Average investment amount
$100
β° Last time a customer invested in CDXDA
990 days
CDXDA investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in CDXDA also invest in...
CardieX Ltd. engages in designing, manufacturing, and marketing medical devices used in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. The company specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Companyβs SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.
π Performance (5Yr p.a)
-13.38%
π Share price
$0.10 AUD
π©Ί HEALTH CARE
CDXNC
CardieX Ltd. engages in designing, manufacturing, and marketing medical devices used in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The company is engaged in designing, manufacturing, and marketing medical devices for use in cardiovascular health management, and the development of clinical and consumer digital health solutions. The company is focused on hypertension, cardiovascular disease, and other vascular health disorders. The company operates through its subsidiaries, including ATCOR and CONNEQT. ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its SphygmoCor technology. Under the ATCOR.X brand, it also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. Its digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patientsβ health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness parameters.
π©Ί HEALTH CARE
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
12.86%
π Share price
$129.54 AUD
π GLOBAL
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
π HIGH PRICE GROWTH
Flight Centre Travel Group Ltd. is engaged in providing travel retailing, wholesaling and corporate travel management services. The company is headquartered in Brisbane, Queensland and currently employs 13,065 full-time employees. The firm's principal activities include travel retailing in both the leisure and corporate travel sectors, plus in-destination travel experience businesses including tour operations, hotel management, destination management companies (DMCs) and wholesaling. Its segments include Leisure, Corporate, and Other. The Leisure segment combines the retail store front and online brands for retail customers, luxury travel brands Travel Associates and Scott Dunn, independent agents and complementary offerings. The Corporate segment includes the FCM brand, Corporate Traveller and other Corporate customer brands. The Other segment includes Brisbane-based and other support businesses, including Supply, that support the global network and also include travel management services which incorporates touring, ground-handling and hotels. Its brands include Flight Centre, Aunt Betty, ignite, and Scott Dunn.
π Performance (5Yr p.a)
-11.72%
π Share price
$15.65 AUD
π¨ HOTELS, RESTAURANTS & LEISURE
VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
π Performance (5Yr p.a)
17.92%
π Share price
$427.61 AUD
π HIGH PRICE GROWTH
β³οΈ DIVERSIFIED
π€ TECHNOLOGY